Axonics receives regulatory approval for fourth-generation rechargeable snm system in australia

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) today announced that it has received regulatory approval from the therapeutic goods administration (tga) for marketing the axonics r20® rechargeable sacral neuromodulation (snm) system in australia to treat adults with overactive bladder and fecal incontinence. the r20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once.
AXNX Ratings Summary
AXNX Quant Ranking